Q1 EPS Forecast for Ocular Therapeutix Lowered by Analyst

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for shares of Ocular Therapeutix in a research report issued on Tuesday, March 4th. HC Wainwright analyst Y. Chen now forecasts that the biopharmaceutical company will post earnings of ($0.30) per share for the quarter, down from their previous forecast of ($0.24). HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix's Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($1.18) EPS.

Separately, JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Ocular Therapeutix presently has an average rating of "Moderate Buy" and a consensus price target of $16.50.

Ocular Therapeutix Stock Performance

Shares of OCUL traded up $0.11 during trading hours on Thursday, hitting $7.65. The stock had a trading volume of 1,467,283 shares, compared to its average volume of 1,552,331. The firm has a 50-day moving average price of $7.74 and a 200 day moving average price of $8.86. Ocular Therapeutix has a fifty-two week low of $4.06 and a fifty-two week high of $11.78. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -5.80 and a beta of 1.34. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Remove Ads

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.

Insider Buying and Selling

In related news, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Donald Notman sold 11,119 shares of the firm's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total value of $86,839.39. Following the sale, the insider now directly owns 193,444 shares of the company's stock, valued at approximately $1,510,797.64. This trade represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,895 shares of company stock valued at $283,772. 3.50% of the stock is owned by corporate insiders.

Institutional Trading of Ocular Therapeutix

Several institutional investors have recently added to or reduced their stakes in the stock. Creative Planning purchased a new position in Ocular Therapeutix in the third quarter valued at $182,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Ocular Therapeutix by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 1,015 shares during the last quarter. Rosalind Advisors Inc. grew its holdings in shares of Ocular Therapeutix by 18.0% during the third quarter. Rosalind Advisors Inc. now owns 885,000 shares of the biopharmaceutical company's stock worth $7,700,000 after purchasing an additional 135,000 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in Ocular Therapeutix during the third quarter worth approximately $70,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Ocular Therapeutix in the 3rd quarter valued at $1,102,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.